Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 70/100

Failure Rate

6.3%

2 terminated/withdrawn out of 32 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

3%

1 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

5 recruiting

Enrollment Performance

Analytics

N/A
14(56.0%)
Phase 1
4(16.0%)
Phase 2
3(12.0%)
Early Phase 1
3(12.0%)
Phase 3
1(4.0%)
25Total
N/A(14)
Phase 1(4)
Phase 2(3)
Early Phase 1(3)
+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (32)

Showing 20 of 32 trials
NCT07106034Phase 2Not Yet Recruiting

Standard Second-line Therapy With ONgericimab and TOripalimab in pMMR/MSS Colorectal Cancer: a Single-arm Phase II Trial

Role: lead

NCT06874673Not ApplicableNot Yet Recruiting

Pronase in Improving Endoscopic Mucosal Clarity During Colonoscopy for Patients with Colitis

Role: collaborator

NCT06039917Not ApplicableRecruiting

Effect of the Automatic Surveillance System on Surveillance Rate of Patients with Gastric Premalignant Lesions

Role: collaborator

NCT06541444Early Phase 1Recruiting

Safety and Efficacy of NK520 to Treat Relapsed/Refractory Acute Myeloid Leukemia

Role: collaborator

NCT06501183Phase 1Recruiting

Anti-CDH17 CAR-T Cell Injection in Patients With CDH17-positive Advanced Malignant Solid Tumors

Role: lead

NCT06487377Phase 1Recruiting

IX001 TCR-T In the Treatment of Advanced Pancreatic Cancer and Colorectal Cancer Induced by KRAS Mutations

Role: lead

NCT06329999Not ApplicableRecruiting

A Prospective, Multicenter, and Exploratory Study of CMGV in the Treatment of Recurrent Adult AML and MDS-EB-2/Elder AML

Role: collaborator

NCT06009146Unknown

Results of Endovascular Treatment for Infrapopliteal Arterial Occlusive Disease.

Role: collaborator

NCT05513612Phase 1Withdrawn

Novel CAR-T Cell Therapy in the Treatment of Hematopoietic and Lymphoid Malignancies

Role: lead

NCT05531708Phase 1Withdrawn

Exploratory Study of Novel MSLN CAR-T Cell Therapy in Patients With MSLN-positive Advanced Refractory Solid Tumors

Role: lead

NCT05670171Not ApplicableUnknown

Debulking Atherectomy Versus Stent Angioplasty for Limb Ischaemia of Diabetic Lower Limb Atherosclerosis-occlusive Disease.

Role: collaborator

NCT05656079Not ApplicableUnknown

To Evaluate the Cardiac Safety of Pegylated Liposomal Doxorubicin Concurrently Plus Trastuzumab and Pertuzumab in the Adjuvant Setting for Early-stage HER-2-positive Breast Cancer: a Multicenter, Randomized Controlled Clinical Study

Role: lead

NCT05473884Unknown

Lesion Preparation in Femoropopliteal Artery Occlusion Disease

Role: lead

NCT05559177Early Phase 1Unknown

An Open, Dose-escalation Clinical Study of Chimeric Exosomal Tumor Vaccines for Recurrent or Metastatic Bladder Cancer

Role: lead

NCT05531344Phase 2Completed

Composite Steep-pulseTreatment Device Used in Patients With Benign Prostatic Hyperplasia

Role: collaborator

NCT05498558Unknown

The Selection of Pregnancy for Patients After Tubal Ectopic Pregnancy Treatment

Role: collaborator

NCT05459441Early Phase 1Unknown

Efficacy and Safety Evaluation of Percutaneous Ommaya Capsule Injection of Autologous Bi-dimensional Specific T Cells in the Treatment of Glioma and in Combination With Pemetrexed in the Treatment of Brain/Meningeal Metastases

Role: lead

NCT05438342Not ApplicableUnknown

An Expanded Clinical Study of Triple Therapy for Refractory Solid Tumors That Failed First-line Treatment for Recurrence and Metastasis

Role: lead

NCT05366244Unknown

An Observational Study in Patients With Mild to Moderate COVID-19

Role: lead

NCT05374772Unknown

A Retrospective Study in Patients With Mild to Moderate COVID-19

Role: lead